I Gede Wikania Wira Wiguna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
I Gede Wikania Wira Wiguna has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ni Wayan Armerinayanti
Department of Pathology, Faculty of Medicine and Health Sciences, Warmadewa University, Indonesia
2 shared publications - Agung Brahmanthya Nadine Kepakisan
Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia
1 shared publication - Christo Timothy Mamangdean
Clinical Clerkship Program, Faculty of Medicine Universitas Udayana, Prof. Dr. I.G.N.G. Ngoerah Central General Hospital Denpasar Bali Indonesia
1 shared publication - Desak Putu Oki Lestari
Department of Anatomical Pathology, Faculty of Medicine and Health Sciences, Warmadewa University, Bali, Indonesia
1 shared publication - I Gede Krisna Arim Sadeva
Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia
1 shared publication - I Komang Raditya Putra Pratama
Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia
1 shared publication
Latest Publications
- Open Access
- 14 July 2026
- Published by Jurusan Analis Kesehatan Poltekkes Kemenkes Denpasar in Meditory : The Journal of Medical Laboratory
- Vol. 14 (1) , 156-177
EFFICACY AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELL (CAR-T) THERAPY IN LYMPHOMA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS
Background: Lymphoma (Hodgkin and non-Hodgkin) is a malignancy of the lymphatic system, with global prevalence reaching 2.8% and mortality rates reaching 248,700 cases each year. Therefore, Chimeric Antigen Receptor-Modified T cell therapy (CAR-T) was developed as a new approach to improve survival rates in lymphoma patients. Objective: This study aimed to evaluate the efficacy and safety of CAR-T cell therapy in lymphoma. Methods: PRISMA 2020 was used in the literature search and systematic review with the keywords "CAR-T Cell Therapy" and "Lymphoma". All statistical analyses were performed with R statistical software version 3.3 and MedCalc software version 22. A p-value ≤ 0.05 was considered statistically significant. Results: There were 16 studies involving 440 patients with lymphoma. The complete response rate was 62% (95% CI 55%-65%, I² = 40%). Meanwhile, cytokine release syndrome (CRS) occurred in 73% of cases (95% CI 49%-88%, I² = 80%). The overall Immune effector cell-associated neurotoxicity syndrome (ICANS) rate was 17% (95% CI 9%-30%, I² = 66%). There is no significant publication bias in all analyses (p-value>0.05). However, these results need to be interpreted with caution, considering the high heterogeneity in the pooled analysis results (I² > 50%).
- 14 July 2026
- Published by Jurusan Analis Kesehatan Poltekkes Kemenkes Denpasar in Meditory : The Journal of Medical Laboratory
- Vol. 14 (1) , 156-177
Open AccessEFFICACY AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELL (CAR-T) THERAPY IN LYMPHOMA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS
Background: Lymphoma (Hodgkin and non-Hodgkin) is a malignancy of the lymphatic system, with global prevalence reaching 2.8% and mortality rates reaching 248,700 cases each year. Therefore, Chimeric Antigen Receptor-Modified T cell therapy (CAR-T) was developed as a new approach to improve survival rates in lymphoma patients. Objective: This study aimed to evaluate the efficacy and safety of CAR-T cell therapy in lymphoma. Methods: PRISMA 2020 was used in the literature search and systematic review with the keywords "CAR-T Cell Therapy" and "Lymphoma". All statistical analyses were performed with R statistical software version 3.3 and MedCalc software version 22. A p-value ≤ 0.05 was considered statistically significant. Results: There were 16 studies involving 440 patients with lymphoma. The complete response rate was 62% (95% CI 55%-65%, I² = 40%). Meanwhile, cytokine release syndrome (CRS) occurred in 73% of cases (95% CI 49%-88%, I² = 80%). The overall Immune effector cell-associated neurotoxicity syndrome (ICANS) rate was 17% (95% CI 9%-30%, I² = 66%). There is no significant publication bias in all analyses (p-value>0.05). However, these results need to be interpreted with caution, considering the high heterogeneity in the pooled analysis results (I² > 50%).
- Open Access
- 30 June 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 18 (2) , 1645-1652
High Cytoplasmic and Membranous Epidermal Growth Factor Receptor (EGFR) Expression as a Risk Factor for High-Grade Ovarian Carcinoma (HGOC)
High-grade ovarian carcinoma (HGOC) is one of the most aggressive grades of ovarian cancer and causes high mortality. The molecular mechanisms underlying the development and progression of high-grade ovarian carcinoma related to high EGFR expression are still not fully understood. This study aimed to evaluate the cytoplasmic and membranous EGFR expression as a risk factor for high-grade ovarian carcinoma. This study employed a case-control design with consecutive sampling among ovarian cancer patients at BaliMed Denpasar Hospital and the Anatomical Pathology Laboratory, Faculty of Medicine and Health Sciences, Warmadewa University. EGFR expression was analyzed immunohistochemically and assessed by H-score. Data were analyzed using the chi-square test and binary logistic regression. P-value ≤ 0.05 was considered significant. This study involved 40 ovarian cancer samples, with the majority (86.7%) aged ≥50 years. The most common histopathological type was endometrioid (45%). As many as 80% of high-grade ovarian cancer (HGOC) cases showed high EGFR expression (>50%), in contrast to low-grade ovarian cancer (LGOC) (40%). High EGFR expression increased the risk of HGOC by 10.5 times (p = 0.001). Multivariate analysis revealed that high EGFR expression was an independent risk factor for HGOC, with an aOR of 41.5 (p-value = 0.008; 95% CI: 2.65–649.14). High EGFR expression was significantly associated with an increased risk of HGOC. Patients with high EGFR expression had a greater risk of HGOC than patients with low to moderate EGFR expression.
- 30 June 2025
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 18 (2) , 1645-1652
Open AccessHigh Cytoplasmic and Membranous Epidermal Growth Factor Receptor (EGFR) Expression as a Risk Factor for High-Grade Ovarian Carcinoma (HGOC)
High-grade ovarian carcinoma (HGOC) is one of the most aggressive grades of ovarian cancer and causes high mortality. The molecular mechanisms underlying the development and progression of high-grade ovarian carcinoma related to high EGFR expression are still not fully understood. This study aimed to evaluate the cytoplasmic and membranous EGFR expression as a risk factor for high-grade ovarian carcinoma. This study employed a case-control design with consecutive sampling among ovarian cancer patients at BaliMed Denpasar Hospital and the Anatomical Pathology Laboratory, Faculty of Medicine and Health Sciences, Warmadewa University. EGFR expression was analyzed immunohistochemically and assessed by H-score. Data were analyzed using the chi-square test and binary logistic regression. P-value ≤ 0.05 was considered significant. This study involved 40 ovarian cancer samples, with the majority (86.7%) aged ≥50 years. The most common histopathological type was endometrioid (45%). As many as 80% of high-grade ovarian cancer (HGOC) cases showed high EGFR expression (>50%), in contrast to low-grade ovarian cancer (LGOC) (40%). High EGFR expression increased the risk of HGOC by 10.5 times (p = 0.001). Multivariate analysis revealed that high EGFR expression was an independent risk factor for HGOC, with an aOR of 41.5 (p-value = 0.008; 95% CI: 2.65–649.14). High EGFR expression was significantly associated with an increased risk of HGOC. Patients with high EGFR expression had a greater risk of HGOC than patients with low to moderate EGFR expression.